Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 62Myelodysplastic Syndromes 33Leukemia, Myelomonocytic, Chronic 16Leukemia 16Recurrence 9Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myelomonocytic, Acute 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Monocytic, Acute 5Hodgkin Disease 5Myeloproliferative Disorders 4Congenital Abnormalities 4Anemia, Refractory, with Excess of Blasts 4Thrombocythemia, Essential 3Primary Myelofibrosis 3Polycythemia Vera 3Lymphoma 3Blast Crisis 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Trastuzumab 5Carboplatin 4toripalimab 2pertuzumab 2pembrolizumab 2Tretinoin 2Paclitaxel 2Immunotherapy 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cytarabine 2130-nm albumin-bound paclitaxel 2zanidatamab 1venetoclax 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1temsirolimus 1talazoparib 1tagraxofusp 1sarilumab 1sargramostim 1pyrotinib 1pexidartinib 1pazopanib 1patritumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Complete Response × Decitabine × Clear all
NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Nanfang Hospital, Southern Medical University

Phase 2 Unknown
100 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡